PMC:7128678 / 2765-3280 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"87","span":{"begin":469,"end":500},"obj":"Gene"},{"id":"88","span":{"begin":502,"end":507},"obj":"Gene"},{"id":"92","span":{"begin":70,"end":80},"obj":"Species"}],"attributes":[{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Gene:59272"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Gene:59272"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T67","span":{"begin":70,"end":80},"obj":"SP_7"},{"id":"T68","span":{"begin":99,"end":103},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T69","span":{"begin":225,"end":234},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T70","span":{"begin":238,"end":247},"obj":"GO:0006897"},{"id":"T71","span":{"begin":278,"end":287},"obj":"GO:0005768"},{"id":"T72","span":{"begin":355,"end":363},"obj":"CHEBI:36357;CHEBI:36357"},{"id":"T73","span":{"begin":469,"end":500},"obj":"PG_10;PR:000003622"},{"id":"T74","span":{"begin":502,"end":507},"obj":"G_3;PG_10;PR:000003622"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":278,"end":287},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma67180"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid_AGAC","denotations":[{"id":"p88102s10","span":{"begin":443,"end":465},"obj":"MPA"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T15","span":{"begin":70,"end":78},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":119,"end":120},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T17","span":{"begin":406,"end":409},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T33","span":{"begin":99,"end":103},"obj":"Chemical"},{"id":"T34","span":{"begin":146,"end":155},"obj":"Chemical"},{"id":"T35","span":{"begin":225,"end":234},"obj":"Chemical"},{"id":"T36","span":{"begin":345,"end":354},"obj":"Chemical"},{"id":"T37","span":{"begin":469,"end":480},"obj":"Chemical"}],"attributes":[{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":443,"end":465},"obj":"http://purl.obolibrary.org/obo/GO_0033578"},{"id":"T4","span":{"begin":452,"end":465},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":22,"end":168},"obj":"Sentence"},{"id":"T25","span":{"begin":169,"end":386},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}

{"project":"2_test","denotations":[{"id":"32251731-16439323-48149934","span":{"begin":165,"end":166},"obj":"16439323"},{"id":"32251731-29940786-48149935","span":{"begin":292,"end":293},"obj":"29940786"},{"id":"32251731-16439323-48149936","span":{"begin":383,"end":384},"obj":"16439323"},{"id":"32251731-16115318-48149937","span":{"begin":510,"end":511},"obj":"16115318"},{"id":"T79534","span":{"begin":165,"end":166},"obj":"16439323"},{"id":"T31422","span":{"begin":292,"end":293},"obj":"29940786"},{"id":"T11075","span":{"begin":383,"end":384},"obj":"16439323"},{"id":"T4317","span":{"begin":510,"end":511},"obj":"16115318"}],"text":"clinical studies [4]. However, the mechanism of action of CLQ against SARS-CoV-2 is unclear as the drug seems to exert a broad range of potential antiviral effects [5]. Therefore, although CLQ is classically considered as an inhibitor of endocytic pathways through elevation of endosomal pH [6], its detailed molecular mechanism of action as an antiviral compound remains unclear [3,5]. Interestingly, CLQ has been shown to interfere with the terminal glycosylation of angiotensin-converting enzyme-2 (ACE-2) [7], w"}